Alnylam Pharmaceuticals (ALNY) Competitors $269.21 -11.75 (-4.18%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$275.20 +5.99 (+2.22%) As of 03/26/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. GILD, VRTX, REGN, BIIB, UTHR, BMRN, INCY, NBIX, EXEL, and EXASShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Alnylam Pharmaceuticals (NASDAQ:ALNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Which has preferable earnings & valuation, ALNY or GILD? Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B15.50-$278.16M-$2.17-124.06Gilead Sciences$28.75B4.73$480M$0.37295.32 Do institutionals and insiders hold more shares of ALNY or GILD? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ALNY or GILD? In the previous week, Alnylam Pharmaceuticals had 18 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Alnylam Pharmaceuticals and 43 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.12 beat Alnylam Pharmaceuticals' score of 0.75 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 24 Very Positive mention(s) 10 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 37 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community prefer ALNY or GILD? Gilead Sciences received 1323 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 76.28% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes115876.28% Underperform Votes36023.72% Gilead SciencesOutperform Votes248176.86% Underperform Votes74723.14% Do analysts prefer ALNY or GILD? Alnylam Pharmaceuticals presently has a consensus target price of $312.30, suggesting a potential upside of 16.01%. Gilead Sciences has a consensus target price of $104.52, suggesting a potential downside of 4.35%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.76Gilead Sciences 0 Sell rating(s) 11 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.72 Is ALNY or GILD more profitable? Gilead Sciences has a net margin of 1.67% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Gilead Sciences' return on equity of 31.63% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Gilead Sciences 1.67%31.63%10.38% Which has more volatility and risk, ALNY or GILD? Alnylam Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. SummaryGilead Sciences beats Alnylam Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.85B$6.90B$5.63B$8.13BDividend YieldN/A2.73%4.55%4.00%P/E Ratio-124.067.1524.5019.08Price / Sales15.50226.93385.3094.71Price / CashN/A65.6738.1634.64Price / Book517.716.486.954.36Net Income-$278.16M$142.41M$3.20B$247.23M7 Day Performance6.16%-2.88%-2.18%-0.32%1 Month Performance13.50%-4.52%3.14%-3.60%1 Year Performance74.37%-8.69%11.29%2.01% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.2598 of 5 stars$269.21-4.2%$312.30+16.0%+77.1%$34.85B$2.25B-124.062,000Analyst UpgradeGILDGilead Sciences4.6071 of 5 stars$106.82-0.2%$104.52-2.2%+50.9%$133.02B$28.75B288.6917,000Positive NewsVRTXVertex Pharmaceuticals3.8865 of 5 stars$512.33+1.8%$506.70-1.1%+19.6%$131.56B$11.02B-232.886,100Positive NewsREGNRegeneron Pharmaceuticals4.8524 of 5 stars$660.88+0.4%$973.13+47.2%-33.6%$72.25B$14.20B17.2611,900Short Interest ↑Positive NewsBIIBBiogen4.9202 of 5 stars$141.71+0.6%$213.33+50.5%-32.8%$20.74B$9.68B12.668,720Positive NewsUTHRUnited Therapeutics4.7764 of 5 stars$320.09+2.3%$388.25+21.3%+25.4%$14.38B$2.88B14.06980Insider TradeShort Interest ↓Positive NewsBMRNBioMarin Pharmaceutical4.9332 of 5 stars$71.99+1.0%$94.00+30.6%-18.5%$13.73B$2.85B32.723,401Analyst RevisionINCYIncyte4.6578 of 5 stars$62.81+1.4%$74.88+19.2%+8.3%$12.16B$4.24B232.652,617Analyst ForecastNBIXNeurocrine Biosciences4.9315 of 5 stars$115.64+3.3%$165.24+42.9%-18.9%$11.53B$2.36B35.151,200Analyst ForecastNews CoveragePositive NewsEXELExelixis4.5635 of 5 stars$37.70+2.0%$37.59-0.3%+56.8%$10.55B$2.17B21.301,220Upcoming EarningsNews CoveragePositive NewsEXASExact Sciences4.6012 of 5 stars$47.11+3.3%$70.83+50.4%-31.1%$8.75B$2.76B-8.466,400Positive News Remove Ads Related Companies and Tools Related Companies Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
